Immunicum AB (1YG0) Price & Analysis

1 Followers

1YG0 Stock Chart & Stats

€0.49

-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.49

-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.35 - €0.87

Previous CloseN/A

Volume0.00

Average Volume (3M)16.00

Market Cap

€33.03M

Enterprise Value€223.69M

Total Cash (Recent Filing)€74.13M

Total Debt (Recent Filing)€18.67M

Price to Earnings (P/E)―

Beta0.30

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.90

Shares Outstanding62,584,580

10 Day Avg. Volume50

30 Day Avg. Volume16

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)0.50

Price to Sales (P/S)0.00

P/FCF Ratio-3.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.15

Revenue Forecast (FY)€230.28K

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetA very low debt-to-equity (~3% TTM) materially reduces solvency and refinancing risk over the next 2–6 months. This balance sheet strength provides durable optionality to fund clinical programs, negotiate partnerships, and avoids immediate liquidity-driven distress.

Reduced Cash Burn TrendOperating and free cash flow remain negative, but the trend of smaller cash burn since 2024 indicates incremental operating improvement. A sustained reduction in burn rate extends runway, lowers near-term dilution risk, and improves probability of advancing trials or securing non-dilutive deals.

Clinical-stage R&D With Partnership OptionalityAs a clinical-stage developer of cell-based immunotherapies, the company’s core value is in its pipeline. Durable strategic options include collaborations, licensing, or asset sales that can fund development and de-risk programs without requiring commercial revenue or immediate product sales.

Bears Say

Revenue Collapse / No Recurring Product RevenueRevenue at or near zero means the business lacks recurring commercial cash flows. Over the medium term this forces reliance on external financing or partnerships to sustain operations, and prevents organic margin improvement from scale or product sales.

Persistent Negative Cash Flow And Operating LossesConsistent negative operating and free cash flow indicate the company is not self-funding its development activities. This structural cash burn constrains strategic flexibility, increases likelihood of dilutive raises, and can slow or halt program progress absent external funding.

Erosion Of Shareholder Value (negative ROE)Sustained negative ROE reflects persistent losses eroding equity value, making future equity raises more dilutive and costly. Over months this undermines investor support and can weaken negotiating leverage in partnerships or licensing transactions.

1YG0 FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was €0.35 and its highest was €0.87 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is €33.03M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is Aug 20, 2026 which is in 48 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on May 08, 2026. The company reported -€0.031 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.031.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 62,584,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -€0.031 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.226%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in DE:1YG0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.